ClinicalTrials.gg
RecruitingNCT07263438PhenixUpdated Nov 17, 2026

Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial

A Phase 2 interventional study of Trimipramine and Cohort 1: Atezolizumab in Glioblastoma and Recurrence Tumor, sponsored by Centre Hospitalier Universitaire Vaudois. Recruiting at 7 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Centre Hospitalier Universitaire Vaudois · Phase 2, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies testing bevacizumab in Glioblastoma — 8 open to participants now, 13 under way, 1 of them phase 3. Bevacizumab · Glioblastoma.

Planned enrollment
35th of 97
59 · median 48
Started
2025
with 1 other
Phase 2
57 of 97
3 open now
Primary completion
2028-03
later than 9 of 12 live
Registered
97th of 97
by date

Among the 97 studies testing bevacizumab in Glioblastoma, this one is the 35th largest by planned enrollment, is one of 2 that started in 2025, is one of 57 in phase 2, reaches primary completion later than 9 of the 12 other live ones, and was the 97th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

8 of the 97 studies testing bevacizumab in Glioblastoma are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing bevacizumab in Glioblastoma, or all of them as a file.
02

Study summary

This is a multicentric phase II open-label clinical trial aiming to assess the efficacy of the combination of trimipramine and atezolizumab with bevacizumab in patients with recurrent glioblastoma. Eligible patients will be assigned to two cohorts depending on whether there is a medical indication for a neurosurgical resection from first recurrent tumor or not.

The aim of the cohort 1 (patients without indication for surgery) is to analyze the clinical efficacy of this triple combination in recurrent glioblastoma. 48 patients will be registered.

The aim of cohort 2 (patients with indication for surgery) is to confirm the level of trimipramine that can be achieved in the tumor tissue and cerebrospinal fluid collected during surgery. At least 5 patients will be registered.

All patients will receive the combination treatment (trimipramine and atezolizumab associated with bevacizumab) for a maximum period of 2 years from registration. The treatment schedule is slightly different for the 2 cohorts because of the neurosurgical resection foreseen for cohort 2 and the requirement to start bevacizumab only after the surgery. After the end of treatment, all patients will be followed up for safety during 90 days from first treatment administration and then up to 3 years from registration.

03

Conditions studied

  • Glioblastoma
  • Recurrence Tumor

Keywords

  • recurrent glioblastoma
  • trimipramine
  • atezolizumab
  • bevacizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed glioblastoma, according to World Health Organization [WHO] 2021 with unequivocal first progression after standard (6 weeks radiotherapy [RT]) with concurrent \& adjuvant temozolomide [TMZ] chemotherapy.
  • Patients must be at least 3 months off the concomitant part of chemo-radiotherapy.
  • Stable or decreasing dose of for 7 days prior to the baseline
  • Magnetic Resonance Imaging [MRI] scan.
  • Maximum dose of dexamethasone (or equivalent) 4 mg at time of inclusion.
  • No surgery or other invasive procedures (major surgical procedure, open or significant traumatic injury) within 4 weeks prior to registration.
  • No core biopsy or other minor surgical procedure within 7 days prior to registration. (Placement of a central vascular access device, if performed at least 2 days prior to trial treatment administration, is allowed).
  • Patients who require anti-convulsant therapy must be taking non-enzyme inducing antiepileptic drugs [non-EIAED]. Patients previously on EIAED must be switched to non-EIAED at least 2 weeks prior to registration.
  • per Response Assessment in Neuro-Oncology [RANO] version 2.0 criteria. Recurrent disease must be at least one bi-dimensionally measurable contrast-enhancing lesion with clearly defined margins by MRI scan, with minimal diameters of 10 mm, visible on 2 or more axial slices 5 mm apart, based on MRI scan done within 28 days prior to registration.
  • performance status 70-100.
  • Adequate bone marrow function: ≥ 1.5 x 10\^9/L, count ≥ 100 x 109/L, ≥ 90 g/L.
  • Adequate hepatic function: total ≤ 1.5 x [ULN] (except for patients with Gilbert's syndrome ≤ 3.0 x ULN), [AST] and alanine transaminase [ALT] and alkaline phosphatase [AP] ≤ 2.5 x ULN.
  • Adequate renal function: estimated [eGFR] ≥ 45 mL/min/1.73 m2 (according to Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula).
  • Urine dipstick for proteinuria \< 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hours urine collection and must demonstrate ≤ 1 g of protein/24 hours.
  • Adequate coagulation function: [INR] ≤ 1.5 x ULN (the ULN for INR is defined with the value 1.2 for all sites, in case no ULN is documented in the laboratory certificates/sheets). Use of full-dose anticoagulants is permitted as long as the INR is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least two weeks before registration, as per American Society for Clinical Oncology [ASCO] guidelines, low molecular weight heparin [LMWH] should be the preferred approach. Concomitant anticoagulation with aspirin (up to 300 mg/day) and anticoagulation with LMWH is allowed.
  • Women of must use highly effective , are not pregnant or breast-feeding and agree not to become pregnant during trial treatment and until 6 months after the last dose of drug. A negative pregnancy test before inclusion into the trial is required for all women of childbearing potential.
  • Men agree not to donate sperm or to father a child during trial treatment and until 6 months after the last dose of investigational drug.
  • Patient is able and willing to swallow trial drug as whole tablet.

Only for Cohort 2:

  • Consent to giving access of part of the tumor tissue and Cerebrospinal Fluid [CSF] obtained during the routine neurosurgical procedure for pharmacology and translational studies. Tumor tissue will only be made available once it is established that enough tumor tissue is available for standard neuropathological analysis.
  • Patients that have a medical indication for a neurosurgical resection from first recurrent tumor.

Exclusion criteria

Exclusion Criteria:

  • Patient must be in first progression/recurrence and have not received more than one (concurrent and adjuvant temozolomide). Treatment of Time to Treatment Failure [TTF] fields (Optune®) is allowed during first line but will be stopped at registration.
  • Patients must not have prostate enlargement with urinary retention or angle-closure glaucoma at registration.
  • Any other experimental drug must be discontinued at least 30 days prior to registration
  • Patients under ongoing treatment with an antidepressant must be eligible for a switch to trimipramine. Patients currently under TriCyclic Antidepressant [TCAs] (amitriptyline, clomipramine, nortriptyline, imipramine), selective serotonin reuptake inhibitors (sertraline, paroxetine, fluvoxamine, citalopram, escitalopram) or serotonin and norepinephrine reuptake inhibitors (venlafaxine, duloxetine) must be weaned off these medications for at least 14 days before the introduction of trimipramine.

Note: Patients treated with fluoxetine prior to enrollment will only be eligible for this trial after a two-month before starting the study treatment.

  • Prior treatment with atezolizumab or any other .
  • Prior treatment with bevacizumab or other Vascular Endothelial Growth Factor [VEGF] inhibitors or VEGF-receptor signaling inhibitors.
  • Concomitant or prior use of medication within 5 half-lives before registration, with the exceptions of intranasal and inhaled .
  • of less than 12 weeks.
  • Active systemic prior . Patients with a prior malignancy (basal cell carcinoma of the skin, squamous carcinoma of the skin or carcinoma in situ of the cervix) and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration.
  • Blood pressure combination treatment with more than two antihypertensive medications or uncontrolled blood hypertension under properly antihypertensive medications.
  • Severe or uncontrolled cardiovascular disease (congestive heart failure [NYHA] III or IV; unstable angina pectoris, history of myocardial infarction within the last six months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).
  • Have a heart rate interval using Fridericia's formula [QTcF] (QTc = QT / RR\^1/3) ≥ 450 msec or other factors that increase the risk of QT prolongation or arrhythmic events (e.g. heart failure, hypokalaemia, familial history of long QT interval syndrome). Patients with bundle branch block and prolonged QTcF are permitted with approval of the sponsor investigator.
  • Presence of a grade 3 atrioventricular [AV] block on [ECG].
  • History of cerebrovascular accident or intracranial haemorrhage within 6 months prior to registration.
  • Known history of [HIV] or active chronic or virus infection or any uncontrolled active systemic infection requiring intravenous antimicrobial treatment.
  • Known history of tuberculosis, known history of primary immunodeficiency, known history of allogeneic organ transplant. Receipt of within 28 days prior to the first dose of atezolizumab administration. Vaccination with inactivated viruses, such as those in the influenza vaccine, are permitted.
  • History of or active auto-immune disease with the exception of diabetes mellitus type II and well controlled hypothyroidism on treatment.
  • Concomitant treatment with strong or moderate cytochrome P450 3A or 2D6 [ or CYP2D6] inducers or inhibitors.
  • Any concomitant drugs for use with the trial drugs according to the approved product information.
  • Monoamine oxidase inhibitors [MAOI] (Rasagiline, or others not approved in Switzerland, such as phenelzine, tranylcypromine, isocarboxazid and selegiline). Of note, MAOI must have been stopped at least 14 days prior to the start of trimipramine.
  • Known to trial drug(s) or to any component of the trial drug(s)
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Recurrent GBM without indication for re-resection

    Eligible patients will receive: trimipramine, bevacizumab and atezolizumab. Trimipramine will be taken orally daily (75 mg the first week and thereafter 150 mg), bevacizumab (15 mg/kg) and atezolizumab (1200 mg) will be administered intravenously every 3 weeks. Maximum treatment duration is 2 years. Patients will undergo clinical examination, vital signs measurements, and clinical laboratory evaluations regularly. Safety events will be collected up to 90 days after treatment end. Neurological assessment, quality of life assessment, brain Magnetic Resonance Imaging \[MRI\] and radiological assessment with Response Assessment in Neuro-Oncology \[RANO\] scale as per local guidelines will be performed every 9 weeks during study treatment administrations. Thereafter, these assessments will be performed every 12 weeks until clinical or radiological recurrence, for up to 3 years after registration.

    Drug: Trimipramine · Biological: Cohort 1: Atezolizumab · Biological: Bevacizumab

  • Experimental
    Cohort 2: recurrent GBm with an indication for re-resection

    Eligible patients will receive: Trimipramine taken orally daily (75 mg the first week and thereafter 150 mg) and atezolizumab (1200 mg) administered intravenously. Neurosurgical resection from first recurrent tumor will be planned 1 cycle after trial treatment start. Trimipramine will be continued during surgery and recovery period (minimum 2 weeks). Atezolizumab will be re-started after a minimum recovery period of 14 days after surgery at a fixed dose of 1200 mg administered intravenously, every 3 weeks. Bevacizumab will be started one cycle after the re-start of atezolizumab, at least 35 days after surgery. It will be administered intravenously at a dose of 15 mg/kg every 3 weeks for a maximum of 32 cycles of 21 days. Patients will undergo clinical and safety follow-up up to 3 years post-registration as for Cohort 1.

    Drug: Trimipramine · Biological: Cohort 2: Atezolizumab · Biological: Cohort 2: Bevacizumab

Interventions

  • DrugTrimipramine

    Trimipramine: daily oral intake at 75mg/ day for 7 days, then at 150 mg/ day

  • BiologicalAtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Atezolizumab: intravenous administration at 1200 mg on the first day of 3-week cycles.

  • BiologicalBevacizumab

    Bevacizumab will be administered intravenously at 15 mg/kg on the first day of 3-week cycles.

  • BiologicalAtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on the first day of 3-week cycles. Administration will occur once, then will be interrupted during a recovery period of 14-days post surgery, and then resumed.

  • BiologicalBevacizumabStudies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Bevacizumab will be administered intravenously at 15 mg/kg on the first day of 3-week cycles. The first administration will take place 5 weeks after surgery.

06

What researchers measure

Primary outcomes

  1. Cohort 1: Progression-free survival rate [PFSR]

    Progression-free survival rate \[PFSR\]: evaluated at 6 months after registration using the Response Assessment in Neuro-Oncology \[RANO\] verion 2.0 critieria

    Time frame: 6 months after last patient's registration

  2. Cohort 2: Level of trimipramine in the tumor tissue and cerebrospinal fluid [CSF]

    Level of trimipramine in the tumor tissue and CSF collected during surgery will be assessed by measuring the trimipramine concentration by laboratory analysis.

    Time frame: 3 months after last patient's surgery

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2028, 28 months after the start.

Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 28 months is below that.

Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Dec 4, 2025
StartActual
Nov 3, 2025
Primary completionEst.
Mar 30, 2028
CompletionEst.
Dec 31, 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • Universitätsspital Basel · Basel, SwitzerlandContact f•••@usb.ch→j•••@usb.ch
  • Bern Inselspital · Bern, SwitzerlandContact d•••@insel.ch · •••9300→d•••@insel.ch · •••4114Contact m•••@insel.ch→B•••@insel.ch
  • HFR Fribourg - Hôpital cantonal · Fribourg, SwitzerlandContact j•••@h-fr.ch→M•••@h-fr.ch
  • Luzerner Kantonsspital · Lucerne, SwitzerlandContact e•••@luks.ch→v•••@luks.ch
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Universitätsspital Basel · Basel, SwitzerlandContact f•••@usb.ch→j•••@usb.ch
    • Bern Inselspital · Bern, SwitzerlandContact d•••@insel.ch · •••9300→d•••@insel.ch · •••4114Contact m•••@insel.ch→B•••@insel.ch
    • HFR Fribourg - Hôpital cantonal · Fribourg, SwitzerlandContact j•••@h-fr.ch→M•••@h-fr.ch
    • Luzerner Kantonsspital · Lucerne, SwitzerlandContact e•••@luks.ch→v•••@luks.ch
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07263438
Responsible party
Andreas Hottinger (Professor in Neuro-Oncology, Centre Hospitalier Universitaire Vaudois) — Principal investigator
First posted
Dec 4, 2025
Start date
Nov 3, 2025
Primary completion
Mar 30, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

Andreas Hottinger, MD, PhD
Contact
andreas.hottinger@chuv.ch
0041 79 556 52 71
Stéphanie Viguet-Carrin, PhD
Contact
stephanie.viguet-carrin@chuv.ch
0041 79 556 45 63

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion